Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation
ACS Infectious Diseases · 12.06.2026 · 12 (6) · 2136-2148
DOI: 10.1021/acsinfecdis.6c00330 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 01.06.2026. Verfasst von Wei Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. Hauptthemen laut MEDLINE: Benzoxazines, Dyslipidemias, Gastrointestinal Microbiome, Colitis, Ulcerative. Die Arbeit nennt 72 Literaturangaben. Gefördert von: Guangdong Provincial Department of Science and Technology, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
- Ribopeutic Inc., Guangzhou International Bio Island, Guangzhou 510005, China.
- State Key Laboratory of Organ Failure Research, Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou 510515, China.
- MOE Key Laboratory of Infectious Diseases Research in South China, Southern Medical University, Guangzhou 510515, China.
ORCID-Profile: Wei Wang, Xiaoge Niu, Binbin Cheng, Xinfeng Xu, Shuwen Liu
Förderung
- Guangdong Provincial Department of Science and Technology
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- Scientific and Technological Planning Project of Guangzhou City
- National Health Commission Capacity Building and Continuing Education Center
Zitieren
APA
Wang, W., Niu, X., Li, S., Cheng, B., Cheng, L., Yang, C., Xu, X., Chang, S., Wang, C., & Liu, S. (2026). Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation. ACS Infectious Diseases, 12(6), 2136-2148. https://doi.org/10.1021/acsinfecdis.6c00330
Vancouver
Wang W, Niu X, Li S, Cheng B, Cheng L, Yang C, et al. Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation. ACS Infectious Diseases. 2026;12(6):2136-2148. doi:10.1021/acsinfecdis.6c00330
BibTeX
@article{Wang2026,
author = {Wang, Wei and Niu, Xiaoge and Li, Shasha and Cheng, Binbin and Cheng, Luping and Yang, Chan and Xu, Xinfeng and Chang, Siqiao and Wang, Chan and Liu, Shuwen},
title = {Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation},
journal = {ACS Infectious Diseases},
year = {2026},
volume = {12},
number = {6},
pages = {2136--2148},
doi = {10.1021/acsinfecdis.6c00330}
}
EUVIMED